IP Library › Granted Patent US 12,266,425
Granted Patent B1
US 12,266,425 · App. 17/343,541 · Granted Apr 1, 2025

T cell receptor sequences diagnostic for COVID-19 and related compositions

Inventors: Harlan S. Robins (Seattle, WA); Mark Klinger (Seattle, WA); Thomas M. Snyder (San Bruno, CA)
Assignee: Adaptive Biotechnologies Corporation
G16B30/00A61K39/4611
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,266,425
App. No.
17/343,541
Granted
Apr 1, 2025
Kind
B1
Abstract

Provided are methods of assessing a biological sample obtained from an individual for the presence of a T cell that expresses a T cell receptor (TCR) comprising a TCRβ CDR3 sequence set forth in Table 1. Such methods further comprise identifying the individual as having COVID-19 when the presence of the TCR is detected. The presence of one or more of these TCRs may be of use in prognosticating severity of COVID-19 in the individual and the individual may be treated based on the expected severity of COVID-19. Treatment methods may include administering to the individual a T cell engineered to express the TCR. Such engineered T cells are also disclosed. Also provided are compositions and multimers that find use, e.g., in practicing the methods of the present disclosure.

Claims (14)

1. A method for treating a subject for COVID-19, comprising:

identifying a subject as having COVID-19 based on a presence of two or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37 in a sample obtained from the subject; and

administering to the subject a COVID-19 therapy comprising remdesivir, protease inhibitors, and/or an anti-SARS-CoV-2 antibody.

2. The method of claim 1 , wherein the identifying is based on the presence of three or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

3. The method of claim 1 , wherein the identifying is based on the presence of four or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

4. The method of claim 1 , wherein the identifying is based on the presence of five or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

5. The method of claim 1 , wherein the identifying is based on the presence of six or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

6. The method of claim 1 , wherein the identifying is based on the presence of seven or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

7. The method of claim 1 , wherein the identifying is based on the presence of eight or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

8. The method of claim 1 , wherein the identifying is based on the presence of nine or more of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

9. The method of claim 1 , wherein the identifying is based on the presence of all ten of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 1, 4, 8, 10, 11, 12, 18, 20, 30, and 37.

10. The method of claim 1 , wherein the therapy comprises remdesivir.

11. The method of claim 1 , wherein the therapy comprises protease inhibitors.

12. The method of claim 1 , wherein the therapy comprises anti-SARS-CoV-2 antibody.

Assignments (2)
SECURITY INTEREST Recorded Sep 15, 2022
From: ADAPTIVE BIOTECHNOLOGIES CORPORATION
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 061449/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2021
From: ROBINS, HARLAN S.; KLINGER, MARK; SNYDER, THOMAS M.
To: ADAPTIVE BIOTECHNOLOGIES CORPORATION
Reel/Frame 058060/0521 →
Continuity (3)
Provisional Application 63111387 · Nov 9, 2020
Provisional Application 63055877 · Jul 23, 2020
Provisional Application 63037563 · Jun 10, 2020
References Cited (62)
US 5858358A · June et al. · 1999 [cited by applicant]
US 5883223A · Gray · 1999 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6692964B1 · June et al. · 2004 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7067318B2 · June et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7172869B2 · June et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 9150905B2 · Robins et al. · 2015 [cited by applicant]
US 9181590B2 · Robins et al. · 2015 [cited by applicant]
US 9181591B2 · Robins et al. · 2015 [cited by applicant]
US 20100330571A1 · Robins et al. · 2010 [cited by applicant]
US 20120058902A1 · Livingston et al. · 2012 [cited by applicant]
US 20130253842A1 · Sherwood et al. · 2013 [cited by applicant]
US 20130288237A1 · Robins et al. · 2013 [cited by applicant]
US 20150203897A1 · Robins et al. · 2015 [cited by applicant]
US 20150299785A1 · Livingston et al. · 2015 [cited by applicant]
WO WO2010151416 · 2010 [cited by applicant]
WO WO2011106738 · 2011 [cited by applicant]
WO WO2012027503 · 2012 [cited by applicant]
WO WO2013169957 · 2013 [cited by applicant]
WO WO2013188831 · 2013 [cited by applicant]
WO WO2014055561 · 2014 [cited by applicant]
WO WO2022150610A2 · 2022 [cited by examiner]
Arstila et al. (1999) “A Direct Estimate of the Human α/β T Cell Receptor Diversity” Science 286(5441): 958-961. [cited by applicant]
Cabaniols et al. (2001) “Most α/βT Cell Receptor Diversity is Due to Terminal Deoxynucleotidyl Transferase” Journal of Experimental Medicine 194: 1385-1390. [cited by applicant]
Carlson et al. (2013) “Using synthetic templates to design an unbiased multiplex PCR assay” Nature Communications 4: 2680, p. 1-9. [cited by applicant]
Chu et al. (1981) “SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen” Gene 13: 197-202. [cited by applicant]
Emerson et al. (2017) “Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire” Nature Genetics 49: 659-665. [cited by applicant]
Govers et al. (2010) “T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing” Trends in Molecular Medicine 16(2): 77-87. [cited by applicant]
Griffoni et al. (2020) “Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individual” Cell;181(7): 1489-1501. [cited by applicant]
Isho et al. (2020) “Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in patients with COVID-19” Science Immunology 5(52): eabe5511, p. 1-14. [cited by applicant]
Iyer et al. (2020) “Persistence and decay of human antibody responses to the receptor binding domain of SARS-COV-2 spike protein in COVID-19 patients” Science Immunology 5(52): eabe0367, p. 1-13. [cited by applicant]
Klinger et al. (2013) “Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells” PLoS One 8(9): e74231, p. 1-9. [cited by applicant]
Klinger et al. (2015) “Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing” PLoS One 10(10): e0141561, p. 1-21. [cited by applicant]
Lavezzo et al. (2020) “Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'” Nature 584: 425-429. [cited by applicant]
Long et al. (2020) “Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections” Nature Medicine 26: 1200-1204. [cited by applicant]
Mulder et al. (2020) “Reinfection of Severe Acute Respiratory Syndrome Coronavirus 2 in an Immunocompromised Patient: A Case Report” Clinical Infectious Diseases: ciaa1538, p. 1-2. [cited by applicant]
Nolan et al. (2020) “A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2” Research Square (1): rs.3.rs-51964 Preprint, p. 1-28. [cited by applicant]
Robins et al. (2010) “Overlap and Effective Size of the Human CD8+ T Cell Receptor Repertoire” Science Translation Medicine 2(47): 47ra64, p. 1-11. [cited by applicant]
Robins et al. (2012) “Ultra-sensitive detection of rare T cell clones” Journal of Immunological Methods 375(1-2): 14-19. [cited by applicant]
Robins et al. (2009) “Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells” Blood 114(19): 4099-4107. [cited by applicant]
Sekine et al. (2020) “Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19” Cell 183(1): 158-168. [cited by applicant]
Seow et al. (2020) “Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans” Nature Microbiology 5: 1598-1607. [cited by applicant]
Sherwood et al. (2011) “Deep Sequencing of the Human TCRγ and TCRβ Repertoires Suggests that TCRβ Rearranges After αβ and γδ T Cell Commitment” Science Translational Medicine 3(90): 90ra61, p. 1-8. [cited by applicant]
Snyder et al. (2020) “Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels” medRxiv (3): Preprint, p. 1-33. [cited by applicant]
Tillett et al. (2020) “Genomic evidence for reinfection with SARS-CoV-2: a case study” Lancet Infectious Diseases 21(1): 52-58. [cited by applicant]
Wang et al. (2016) “Phase 1 studies of central memory-derived CD19 Car T-cell therapy following autologous HSCT in patients with B-cell NHL” Blood 127(24):2980-2990. [cited by applicant]
Weiskopf et al. (2020) “Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome” Science Immunology 5(48): eabd2071, p. 1-14. [cited by applicant]
World Health Organization (2020) “Coronavirus disease 2019 (COVID-19) Situation Report—94” 12 pages. [cited by applicant]
World Health Organization (2020) “Virtual press conference on COVID-19—Mar. 11, 2020” 17 pages. [cited by applicant]
Zhang et al. (2019) “The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review” Technology in Cancer Research & Treatment (18):1533033819831068, p. 1-13. [cited by applicant]
Zhao et al. (2019) “Engineered T Cell Therapy for Cancer in the Clinic” Frontiers in Immunology (10):2250, p. 1-20. [cited by applicant]
Zuo et al. (2020) “Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection” bioRxiv preprint, 25 pages. [cited by applicant]